What is the recommended initiation and titration regimen for glyburide in a non‑pregnant adult with type 2 diabetes, estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m², no sulfonylurea allergy, and ability to recognize and treat hypoglycemia?

Glyburide Initiation and Titration Regimen

Start glyburide at 2.5 to 5 mg once daily with breakfast or the first main meal, then titrate upward by no more than 2.5 mg increments at weekly intervals based on blood glucose response, with a usual maintenance dose of 1.25 to 20 mg daily. 1

Initial Dosing

• Standard starting dose: 2.5 to 5 mg once daily, administered with breakfast or the first main meal 1
• For patients at higher risk of hypoglycemia: Start at 1.25 mg daily 1
  • This lower starting dose applies to elderly patients, those with hepatic or renal impairment, or those more sensitive to hypoglycemic effects

Titration Strategy

• Titration increments: Increase by no more than 2.5 mg at weekly intervals 1
• Titration guidance: Base dose adjustments on the patient's blood glucose response 1
• Monitoring frequency: Blood glucose must be monitored periodically (not just urinary glucose) to determine the minimum effective dose 1
• Glycated hemoglobin: May also be valuable in monitoring response to therapy 1

Maintenance Dosing

• Usual maintenance range: 1.25 to 20 mg daily 1
• Dosing frequency: May be given as a single dose or in divided doses 1
• Timing: Administer with meals to minimize hypoglycemia risk

Critical Safety Considerations

Hypoglycemia Risk

• Sulfonylureas carry high hypoglycemia risk and should be used with caution in individuals at risk for hypoglycemia, particularly when combined with insulin 2
• Weight gain is expected with glyburide therapy 2
• Failure to follow appropriate dosage regimens may precipitate hypoglycemia 1
• Patients who do not adhere to prescribed dietary and drug regimens are more prone to unsatisfactory response 1

Renal Function Considerations

• Glyburide is generally not recommended in chronic kidney disease 2
• While your patient has eGFR ≥60 mL/min/1.73 m², be aware that other second-generation sulfonylureas (glipizide, glimepiride) should be initiated conservatively in any degree of renal impairment 2
• This makes glyburide a less-than-ideal choice even with normal renal function, as it lacks the flexibility for dose adjustment if kidney function declines

Drug Interactions

• Colesevelam interaction: If the patient is taking colesevelam, glyburide must be administered at least 4 hours prior to colesevelam, as colesevelam reduces maximum plasma concentration and total exposure to glyburide 1

Monitoring Parameters

• Blood glucose monitoring: Essential for detecting primary failure (inadequate glucose lowering at maximum dose) and secondary failure (loss of adequate response after initial effectiveness) 1
• Reassessment schedule: Evaluate and modify therapy regularly every 3-6 months to avoid therapeutic inertia 2
• A1C monitoring: Use to assess overall glycemic control and response to therapy 1

Important Clinical Context

While glyburide can be initiated using the above regimen, current guidelines position sulfonylureas as having high hypoglycemia risk with neutral effects on cardiovascular outcomes, heart failure, and kidney outcomes 2. The 2025 American Diabetes Association guidelines note an FDA special warning on increased cardiovascular mortality risk based on older sulfonylurea studies, though glimepiride has been shown to be cardiovascular-safe 2. Given these considerations and the availability of agents with superior safety profiles (GLP-1 receptor agonists, SGLT2 inhibitors), glyburide should typically be reserved for situations where cost, access, or patient preference preclude use of preferred agents.